

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 015280-367200US
Client Ref. No.: E-232-98/1

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On

June 20, 2003
TOWNSEND and TOWNSEND and CREW LLP

By: Shane Lane

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Wang *et al.*

Application No.: Not yet assigned

Filed: Herewith

For: METHODS FOR IDENTIFYING
INHIBITORS OF GADD45
POLYPEPTIDE ACTIVITY, AND
INHIBITORS OF SUCH ACTIVITY

Examiner: Not yet assigned

Art Unit: Not yet assigned

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

PRELIMINARY AMENDMENT

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In order to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, mailed February 24, 2003, Applicants submit that the computer-readable form in the instant application is identical with that filed in Application No. 09/534,811, filed February 26, 2001. In accordance with 37 C.F.R. § 1.821(e), please use the computer-readable form filed in Application No. 09/534,811 as the computer-readable form for the instant application. A paper copy of the Sequence Listing from Application No. 09/534,811 is submitted herewith. The

information in the paper copy of the Sequence Listing is identical to that which is in the computer readable form, as required under 37 C.F.R. § 1.821(f).

It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for the computer-readable form that will be used for the instant application.

Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

Amendments to the Specification begin on page 3 of this paper.

Amendments to the claims begin on page 16 of this paper.

Remarks begin on page 19 of this paper.